NCT00263146

Brief Summary

Acute Respiratory Distress Syndrom is associated to lung and systemic inflammation, which could be worsened by mechanical ventilation.This included a proteasis - antiproteasis imbalance which could participate to a fibrosis process. Low tidal-volume ventilation (6 mL/kg) with low plateau pressure (\< 30 cm H2O) has been proved to decrease mortality when compared with more conventionnal high-volume (12 mL/kg) ventilation.Moreover, this lung-protective approach decrease lung annd systemic inflammation. Using recruitment maneuvers (i.e. the application during a short time of high pressures with the intention to re-open the lung, followed by an increase of PEEP-level to keep the lung open, in an attempt to decrease the alveolar shear-stress) has been proposed to improve oxygen and to reduce bio-trauma. However, the effect of such maneuvers on the inflammatory response and on the evolution of ARDS remains unknown. Therefore we have planned a randomized, monocentric, controlled trial consisting of the comparison of two approaches of mechanical ventilation in Acute Lung Injury. This trial will include 30 hemodynamically stable patients fulfilling the ALI or ARDS criteria defined by the US and European Consensus Conference. They will be randomized in two groups: standard low-volume ventilation vs. recruitment maneuvers. The main objective of our study is to compare both ventilatory strategies in termes of lung and systemic inflammation. The primary outcome measures will be the proteasis activity as measured in broncho alveolar fluid (BAL) and pro- and antiinflammatory cytokines activity as measured in the BAL and in the blood. Two samples (BAL and blood) will be obtained at a 48-72 hours interval. In the recruitment maneuver group, the first BAL will be obtained two hours before the maneuver. Secondary outcome measures will be gaz exchange, respiratory mechanics, systemic hemodynamics and visceral dysfunction scores.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2005

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2005

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

December 5, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 7, 2005

Completed
25 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2006

Completed
Last Updated

January 16, 2017

Status Verified

February 1, 2010

Enrollment Period

4 months

First QC Date

December 5, 2005

Last Update Submit

January 13, 2017

Conditions

Outcome Measures

Primary Outcomes (2)

  • proteasis activity as measured in broncho alveolar fluid (BAL)

  • pro- and antiinflammatory cytokines activity as measured in the BAL and in the blood.

Secondary Outcomes (4)

  • gaz exchange

  • respiratory mechanics

  • systemic hemodynamics

  • visceral dysfunction scores.

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age over 18
  • hospitalization in the ICU
  • under mechanical ventilation
  • Acute Lung Injury (ALI)criteria
  • first week of ALI
  • hemodynamic stability (mAP \> 75 mmHg since one hour)
  • informed consent signed (patient or relatives)

You may not qualify if:

  • pregnancy
  • obesity (BMI \> 40 kg/M2)
  • high probability of D-28 death
  • severe burn injury
  • severe hepatic cirrhosis (Child-Pugh C)
  • aplasia
  • HIV or CHV infection
  • use of more than 0.5 mg/kg of steroïds
  • immunosuppressor agents
  • hemopathy
  • contra indications for BAL
  • contra indications for recruitment maneuvers
  • baro-traumatism
  • left cardiac failure
  • chronic respiratory failure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital of Tours

Tours, 37044, France

Location

MeSH Terms

Conditions

Acute Lung Injury

Condition Hierarchy (Ancestors)

Lung InjuryLung DiseasesRespiratory Tract Diseases

Study Officials

  • Gilles Rival, MD

    University Hospital of Tours

    PRINCIPAL INVESTIGATOR
  • Pierre-Francois Dequin, MD, PhD

    University Hospital of Tours

    STUDY CHAIR
  • Francis Gauthier, PhD

    Inserm U-618

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 5, 2005

First Posted

December 7, 2005

Study Start

September 1, 2005

Primary Completion

January 1, 2006

Study Completion

January 1, 2006

Last Updated

January 16, 2017

Record last verified: 2010-02

Locations